Treatment > Doxorubicin · Temozolomide Clinical Trials

Meeting Abstract

Combination temozolomide (T) and pegylated liposomal doxorubicin (C) in patients with recurrent glioblastoma multiforme (GBM)

S. L. Chua, M. A. Rosenthal, D. Ashley, A.-M. Woods, A. Dowling, L. Cher

Centre Developmental Cancer Therapeutics; The Royal Melbourne Hospital, Melbourne, Australia; Royal Children's Hospital, Melbourne, Australia; St Vincent's Hospital, Melbourne, Australia; Austin and Repatriation Medical Centre, Melbourne, Australia.

T has established activity in the treatment of recurrent GBM.
Caelyx (C), a liposomal doxorubicin, has established activity in a broad range of tumours but has not been extensively evaluated in the treatment of GBM.
Phase I data suggest that T and C can be combined safely at full dose.
Combination T (200 mg/m2 orally Day 1-5) and C (40 mg/m2 IV Day 1) was given q4 weekly in patients (pts) with recurrent GBM.
Currently, 22 pts have received a total of 103 cycles (median 3 cycles) with 3 patients receiving treatment.
The median age was 55 years (range 31-80 years) and 17 were male.
All pts had received radiotherapy, but only two had received prior chemotherapy.
1 patient (pt) had a complete response (5%), 3 pts had partial responses (14%), and 11 pts had stable disease (50%).
The median time to progression for the cohort is 3.2+ months (range 1-13+ months).
Seven pts (32%) were progression-free at 6 months.
Hematological toxicity included: Grade 3/4 neutropenia in 4 pts (19%), Grade 3/4 thrombocytopenia in 4 pts (18%).
Grade 3 non-hematologic toxicity included: rash in 3pts (14%), nausea and vomiting in 1pt (5%), hypersensitivity reaction to Caelyx in 3pts (14%) and palmar-plantar toxicity in 1pt (5%).
In conclusion, the combination of T and C is well tolerated and has significant activity in the treatment of recurrent GBM.

© Copyright 2003 American Society of Clinical Oncology All rights reserved worldwide